Schizophrenia: 2025 Progress in Negative Symptom Treatment, Coordinated Care, and Precision Approaches

Dr. Matcheri Keshavan

Year-End Review of Schizophrenia Treatment & Research in 2025

It’s been a quietly important year – though not with a single breakthrough – but with multiple streams converging, reshaping how we think, diagnose, and treat schizophrenia. We are witnessing the end of the dopamine era, the rise of precision psychiatry, and – importantly – the expansion of real-world, scalable care models.

1. Beyond Dopamine

For over 60 years, virtually all antipsychotics shared a common denominator: D2 receptor blockade. 2025 marks something historic: the first truly viable non-dopaminergic antipsychotic in clinical use. Cobenfy™ – also known as xanomeline–trospium – a combined M1/M4 muscarinic agonist with peripheral blockade to reduce side effects. After its late 2024 approval, this year brought guidance on how to use it, who benefits most, and how to manage its GI side effects. What’s intriguing is that patients with prominent negative symptoms seem to respond particularly well. We’re seeing the first signs of treatment stratification – matching interventions to symptom profiles, perhaps even to biological signatures in the near future.

Ulotaront, a TAAR1 and 5-HT1A agonist: The results so far in 2025 confirm good tolerability and modest benefits – especially in those with milder psychosis or those who can’t tolerate dopamine blockers. It’s not widely approved yet, but remains very much alive.

These studies provide the proof of concept that schizophrenia can be effectively treated without dopamine antagonism. This opens the door toward mechanistically diverse antipsychotics, and possibly, symptom-specific treatment strategies.

• Halassa, M.M. Preliminary real-world predictors of response to muscarinic targeting in psychosis. Nat. Mental Health (2025). https://doi.org/10.1038/s44220-025-00529-w

• Hsu YC, Hung TY, Chen YB, Hung KC, Liang CS, Tseng PT, Tu YK, Correll CU, Hsu CW, Solmi M. Trajectory of efficacy and safety across ulotaront dose levels in schizophrenia: a systematic review and dose-response meta-analysis. Int J Neuropsychopharmacol. 2025 Sep 1;28(9):pyaf059. doi: 10.1093/ijnp/pyaf059. PMID: 40795331; PMCID: PMC12421877.

2. Long-Acting Injectables

Six-month paliperidone now has real-world 3-year follow-up data, demonstrating stable symptom control, lower hospitalization rates, and predictable tolerability. Olanzapine LAI – long delayed due to post-injection delirium risks – made a comeback. New Phase 3 data show no observed cases of PDSS across thousands of injections. If approved, this could finally make olanzapine, one of the most effective antipsychotics, practically available in LAI form.

Thus, practice guidelines are shifting: LAIs are no longer seen as “last-resort adherence tools” but increasingly as first-line maintenance options, especially when the goal is sustained functional recovery. In chronic psychosis, dosing every 6 months may soon become routine. We’re moving toward a future where non-adherence is treated as a medical risk factor – just like dropping out of insulin treatment for diabetes.

• New Long-term Safety Data from the Completed Phase 3

• Kane JM, Agid O, Castle DJ, Citrome L, Fagiolini A, Kishimoto T, Larrauri CA, Leucht S, Rubio JM, Sajatovic M, Schooler N, Correll CU. The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment. Neurol Ther. 2025 Dec;14(6):2551-2581. doi: 10.1007/s40120-025-00838-3. Epub 2025 Oct 7. PMID: 41057718; PMCID: PMC12623523.

3. Digital Therapeutics (DTx)

One major development is CT-155, a smartphone-based prescription digital therapeutic targeting negative symptoms – particularly motivation and engagement. It met its primary endpoint in a Phase 3 trial and now has Breakthrough Device designation from the FDA. Other tools, such as SlowMo – a digital reasoning-based therapy for paranoia – have published high-quality RCT data demonstrating real-world improvements when added to treatment-as-usual. Moreover, apps using ecological momentary interventions – tiny push notifications with structured prompts, mindfulness cues, cognitive reframing – are being tested in several domains: motivation, social functioning, coping with hallucinations.

Digital interventions are no longer just “apps for wellness.” They are slowly becoming prescribable, evidence-based, reimbursable tools — especially for treating negative symptoms and social withdrawal, where medication alone is weak.

• Lakhan SE, Dorner-Ciossek C, Besedina O, Dickerson F, Hastedt C, Isla R, Kahn RS, Lindenmayer JP, Mehta R, Snipes C, Speier A, Tang W, Willis B, Fernandez JW, von der Goltz C, Pratap A Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial JMIR Res Protoc 2025;14:e81293
  doi: 10.2196/81293PMID: 41057039PMCID: 12541272

4. Brain Stimulation: A Growing Electroceutical Toolbox

Another major movement in 2025: accelerated TMS and theta-burst stimulation for negative symptoms. Intermittent theta-burst stimulation (iTBS) to the dorsomedial prefrontal cortex – especially using accelerated multi-session protocols – is showing clinically meaningful reductions in negative symptoms. Safety is no longer a major concern – 2025 meta-analyses confirm low seizure risk and good tolerability. The field is now asking: Which patients benefit most? Which brain targets? Which stimulation parameters? Precision is replacing general enthusiasm. This marks the beginning of an “electroceutical era” in schizophrenia care – still early, still mostly off-label – but increasingly structured, protocol-driven, and measurable.

• Li J, Jiang D, Huang X, Wang X, Xia T, Zhang W. Intermittent theta burst stimulation for negative symptoms in schizophrenia patients with moderate to severe cognitive impairment: A randomized controlled trial. Psychiatry Clin Neurosci. 2025 Apr;79(4):147-157. doi: 10.1111/pcn.13779. Epub 2025 Jan 30. PMID: 39887864.

5. Biomarkers and Precision Psychiatry

Three trends dominate: Exosomal microRNAs – increasingly studied in relation to psychosis onset, cognitive deficits, and synaptic dysfunction. In AI-driven analyses — especially ensemble models — these miRNA signatures can discriminate risk states with growing accuracy. Polygenic risk scores – not clinically decisive yet — but when combined with clinical features or treatment trajectories, such as clozapine response, they begin to inform treatment stratification. Real-world data + clinical phenotyping – analyses of muscarinic agonist responses hint at early efforts to match treatment to patient phenotype, based on patterns like prominent negative symptoms or substance use history. Overall, psychiatry is edging closer to “precision psychiatry”, although this is not yet ready for routine care.

• Adly NM, Khalifa D, Abdel-Ghany S, Sabit H. MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia. J Neural Transm (Vienna). 2025 Aug 8. doi: 10.1007/s00702-025-02993-1. Epub ahead of print. PMID: 40779062.

• Năstase MG, Vasile AI, Pietreanu AC, Trifu S. Following the Action of Atypical Antipsychotic Clozapine and Possible Prediction of Treatment Response in Schizophrenia. Life (Basel). 2025 May 22;15(6):830. doi: 10.3390/life15060830. PMID: 40566484; PMCID: PMC12194553.

6. The Rise of Early Psychosis Programs

Coordinated Specialty Care – CSC – has now firmly established itself as the gold standard for first-episode psychosis. In 2025, the conversation moved from “Does this work?” to “How do we scale and sustain it?”. Policy frameworks now focus on: Financial models for sustained CSC funding, Training and retention of workforce, and Integration of family support, vocational therapy, and digital engagement. If implemented widely, CSC may improve outcomes, by catching psychosis early, shortening duration of untreated illness, and restoring role functioning.

• Srihari VH, Keshavan MS. Learning health systems for first-episode psychosis: Insights from North America. Schizophr Res. 2025 Dec;286:A1-A5. doi: 10.1016/j.schres.2025.10.025. Epub 2025 Nov 11. PMID: 41224594.

• Scaling-CSC-for-FEP-Insights-from-a-National-Impact-Model.pdf

• Coordinated Specialty Care: Paving the Way for Psychosis Recovery | Psychiatric Times

Catatonia

Jo Ellen Wilson, MD, PhD, MPH

Dr. Wilson will review the epidemiology of catatonia, its clinical presentation, diagnostic approach and treatment recommendations. She will also share highlights from the recently published American Psychiatric Association Resource Document for catatonia.

Dr. Jo Ellen Wilson is a Consultation Liaison Psychiatrist, Epidemiologist at Vanderbilt and a Physician Scientist at the Veterans Affairs (VA) Geriatric Research, Education and Clinical Center (GRECC) with a research focus on acute and chronic forms of brain dysfunction that occurs as a part of critical illness and aging.  Dr. Wilson completed medical school, general adult psychiatry residency and a consultation liaison psychiatry fellowship at Vanderbilt.  After joining the Vanderbilt faculty in 2014, Dr. Wilson completed a master's in public health (MPH; 2016), PhD in Epidemiology (2023), and post-doctoral research fellowship at the VA GRECC.  

Dr. Wilson's recent research has focused on acute brain dysfunction (catatonia, delirium and coma) in the setting of critical illness in her prospective cohort study ("Delirium and Catatonia Prospective Cohort Study"), now serving as the co-Principal Investigator on a trial ready cohort for Down Syndrome and clinical trials using novel therapeutics to reduce the risk of Alzheimer’s Disease in middle aged adults with Down Syndrome.  

Zoom Link

From Policy to Practice: Implementing Team-Based Bundled Rates in Early Psychosis Care

Lauren Finke and Amanda Weber

This session explores strategies for advancing sustainable financing models for Coordinated Specialty Care (CSC) and early psychosis programs through team-based bundled payment structures. Lauren Finke with the Kennedy Forum will share policy recommendations and advocacy priorities to facilitate commercial reimbursement for CSC services. Following that, Amanda Weber, Director of Early Psychosis Services Hub at the Brookline Community Mental Health Center, will offer a real-world perspective on navigating insurance systems and successfully securing a bundled-rate contract by highlighting lessons learned.

Harm Reduction as an Effective & Expansive Community Health Practice

Mass-STEP Conference Day 2

Riot Diaz, Loc Ironwood, Vera Muñiz-Saurré & Jill Shanahan
Moderated by Lionel Frechette

Therapeutic Alliance in Early Psychosis: Clinical, Research, and Lived Experience Perspectives

Mass-STEP Conference Day 2

Nate Schwirian, Charles Stromeyer, Kim Mueser PhD, Julia Browne PhD
Moderated by Raquelle Mesholam-Gately, PhD

Toward an Early Intervention Continuum of Care

2025 Mass-STEP Conference Day 2

Robert Heinssen, PhD

Bridges to the Future: Sustaining the Benefits of Early Intervention after First Episode Psychosis Care

2025 Mass-STEP Conference Day 2

Drs. Merete Nordentoft, Eric Chen, & Dost Ongur
Moderated by Matcheri Keshavan, MD

Community Spotlight: Emerging Innovations

2025 Mass-STEP Conference Day 1:

Pediatric Primary Care and Coordinated Specialty Care: What Can We Learn From Each Other?

Emily Kline, PhD

2025 Mass-Step Conference Day 1:

Comparative Effectiveness of Cognitive Remediation & Social Skills Training in Schizophrenia

Drs. Russell Schutt & Matcheri Keshavan

The presenters will provide an overview of Project SUCCESS, a comparative effectiveness trial of cognitive remediation and social skills training for individuals with schizophrenia, including preliminary results on the effectiveness of cognitive enhancement training (CET) and the moderators of effectiveness for these interventions.

ADHD and Psychosis: Risk, Comorbidity, and Treatment

Dr. Oscar Buckstein, MD

Dr. Bukstein will discuss ADHD as a risk factor for the development of psychotic disorders, patterns of comorbidity, and their treatment.

 Dr. Bukstein is currently Senior Attending Psychiatrist in the Department of Psychiatry and Behavioral Sciences at Boston Children’s Hospital (BCH). and Professor of Psychiatry at Harvard Medical School.

At BCH, Dr. Bukstein has served a Vice-Chair, Director of the Child and Adolescent Psychiatry Fellowship, and Director of Outpatient Services. Prior to coming to Boston Children’s Hospital (BCH) in March 2016, Dr Bukstein spent several years in Houston, Texas at the University of Texas (UT) Health Science Center in Houston where he was Professor of Psychiatry and Chief of the Division of Child and Adolescent Psychiatry and at DePelchin Children’s Center where he was Medical Director. He spent 28 years at the Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh and the University of Pittsburgh School of Medicine.

Dr. Bukstein has over 35 years of practice experience with particular clinical and research expertise in treating youth with substance use disorders, attention deficit hyperactivity disorder, aggressive behavior, and disruptive behavior disorders. Dr. Bukstein has a substantial academic record, having authored or co-authored over 200 papers, chapters, or books or other academic products and has received funding by the National Institute of Mental Health, the National Institute on Drug Abuse, the National Institute of Alcohol Abuse and Alcoholism, and the National Institute on Child Health and Human Development.

Register Here: https://us02web.zoom.us/meeting/register/O-BstWkHR6uaSlm0cFllAA

Biomarkers and their potential value in diagnosis and treatment of psychosis disorders

Matcheri S. Keshavan MD, Stanley Cobb Professor and Academic Head of Psychiatry, Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Harvard Medical School

Psychiatric diagnosis is still symptom-based, and generally has limited value in treatment selection and outcome prediction.  In this presentation, the potential value of biomarkers will be discussed, especially as they pertain to the diagnosis and treatment early course psychotic disorders.

The 10 C's of Psychosis Psychopharmacology

Dr. Matcheri Keshavan, hosted by VuMedi

Childhood-Onset Bipolar Disorder, ADHD and Psychotic Illness

Dr. Janet Wozniak, MD

As many as 2/3 of adults seen for bipolar clinical services had a pediatric onset to their illness. Psychosis has been reported in 15%-60% children and young adolescents with bipolar disorder.  Pediatric onset bipolar disorder has high rates of comorbidity with ADHD, which can continue into adult years.  Despite high rates of persistence and morbidity, there is skepticism as to whether bipolar disorder can start in the early years of life.  This presentation will discuss the course, characteristics and validity pediatric onset bipolar disorder with a focus on continuity into adult years. 

Dr. Janet Wozniak received her undergraduate degree from Harvard College, and her medical training at Cornell University Medical College. Dr. Wozniak completed her adult and child psychiatry training at Massachusetts General Hospital (MGH). She has since received an Eli Lilly Pilot Research Award, the Elaine Schlosser Lewis Award and Claflin Distinguished Scholar Award. At MGH, she is the director of the Pediatric Bipolar Disorder Clinical and Research Program and the director of the Child and Adolescent Psychiatry Outpatient Service. Dr. Wozniak’s research focuses on the characteristics, longitudinal course and treatment of pediatric bipolar disorder. Widely regarded as a national expert on the topic of pediatric bipolar disorder and attention deficit/hyperactivity disorder, Dr. Wozniak is the author of dozens of scientific articles.
Full Biography

Zoom Link: https://harvard.zoom.us/meeting/register/dB_fyeJXT56ysa_qpHA5yQ

Diagnostic Considerations in Early Psychosis

Emily Gagen, Ph.D. and Amanda Weber Ph.D.

In this presentation, we will explore diagnostic considerations in early psychosis, emphasizing the importance of applying a developmental and pediatric lens. This perspective is essential for accurately understanding the unique presentation of symptoms in adolescents and young adults and avoiding premature or inaccurate labeling. We will also highlight the critical role of differential diagnosis in providing thoughtful, individualized care—ensuring that diagnoses are not only accurate, but developmentally appropriate and responsive to the broader context of each young person’s life.

Emily Gagen, Ph.D. (she/her), is a licensed clinical psychologist at the Brookline Center for Community Mental Health. She is the director of the Massachusetts Psychosis Access and Triage Hub (M-PATH) and is also a member of the team at the CEDAR Clinic, where she conducts diagnostic evaluations, provides individual psychotherapy to CEDAR clients, and supervises trainees. 

Amanda M. Weber, Ph.D. (they/them), is a licensed counseling psychologist at the Brookline Center for Community Mental Health. They are the director of the CEDAR Clinic and also co-lead the Massachusetts Psychosis Prevention Partnership (M3P). Currently, they supervise trainees, conduct psychiatric evaluations for youths and young adults, and provide individual, group, and family therapy.

Patient Retention and Family Engagement in Coordinated Specialty Care: Best Practices from Massachusetts Programs

Cheryl Y. S. Foo, PhD

Patient and family disengagement from coordinated specialty care (CSC) are common and compromise recovery from a first-episode of psychosis. This presentation will share findings from Massachusetts CSC programs on program characteristics, services, and strategies that promote patient retention and family engagement. 

 Cheryl Y. S. Foo, PhD, is a clinical psychologist and researcher focused on making evidence-based treatments for individuals with serious mental illness more accessible and used in community care settings. She is the Associate Director of the Massachusetts General Hospital (MGH) Center of Excellence for Psychosocial and Systemic Research, Director of Family Services of the MGH First Episode and Early Psychosis Program, and an Instructor in Psychology at Harvard Medical School.

Utility of Neuropsychological Assessment in Psychotic Spectrum Disorders

Drew Coman, PhD

View Slides

This presentation will aim to enhance clinicians' knowledge of neurocognitive functioning in psychotic spectrum disorders as well as best practices in neuropsychological testing. Dr. Coman will describe the IEP and 504 processes within schools and resources to support our patients in school and/or workplace settings, including strategies to advocate for necessary school-based accommodations and resources.

Dr. Drew Coman is the Director of Child & Adolescent Psychology and Neuropsychology at MGB/HMS's Psychosis and Clinical Research Program (PCRP).  He received his undergraduate degree with Departmental Honors at the University of Miami and also completed his graduate studies there in Child Clinical Psychology.  He concluded his training with a pre-doctoral internship/residency and a postdoctoral fellowship at the MGH/HMS.  He has been a faculty at MGH/HMS since 2014.  Dr. Coman has training and expertise in conducting comprehensive neuropsychological and educational evaluations for a myriad of neurodevelopmental disorders, major psychiatric conditions, as well as learning and language-based learning profiles.  

Learning Health Systems for Serious Mental Illness

Matcheri S. Keshavan, MD
Case Presentation by Jose Hidalgo, MD

Learning Objectives:

At the end of this presentation, participants will:

1. Explain key principles of implementation science and their application to improving care for serious mental illness (SMI).

2. Describe the role of Learning Health Systems (LHS) in integrating data and feedback to enhance SMI treatment.

3. Identify implementation strategies and barriers to translating evidence-based practices into psychiatric settings.

Psychedelics & Early Course Psychosis

This panel, moderated by Dr. Matcheri Keshavan, will bring together experts with backgrounds in psychiatry, lived experience, and indigenous communities discuss the historical and current uses of psychedelic substances, potential risks and benefits, and approaches to discussing psychedelic use with individuals in early-course psychosis care. The panelists include:

 Ryan Henner, MD Psychiatrist
Hyun Jung Kim, MD Psychiatrist
Raul Condemarin, MD Psychiatrist
Vera Muniz Suarre, CPS, MPH Lived Experience Expert
Darlene Flores DC, Traditional Medicine Keeper

Register here for Zoom link: https://harvard.zoom.us/meeting/register/nTVuFYJGRFSLbs8A4Ip0eg

Expanding Early Psychosis Resources for Spanish-Speaking Clients & Clinicians

Bernalyn Ruiz-Yu (PhD) & Joey Rodriguez

View Slides

In this call, Bernalyn Ruiz-Yu, PhD and Joey Rodriguez will discuss the needs of Spanish-speaking clients and clinicians in early psychosis programs in Massachusetts. Findings from SALUD advisory board focus groups will be presented. 

Dr. Bernalyn Ruiz-Yu is an Attending Psychologist and Instructor at Boston Children's Hospital, Harvard Medical School. As a clinician, she has experience working with diverse patients of all ages with a particular interest in helping adolescents experiencing psychosis and those identified as being at risk of developing psychosis. As a researcher, she seeks to improve mental health treatment for all children experiencing psychosis and has expertise in serious mental illness in adolescents and interventions. She completed her PhD at the University of Massachusetts, Boston and her doctoral internship and T32 fellowship at the University of California, Los Angeles in adolescent serious mental illness. 

Cobenfy: A Discussion on the Newest Treatment for Schizophrenia

Panel moderated by Matcheri Keshavan, MD

Oliver Freudenreich, MD Psychiatrist
Peter J Weiden, MD Psychiatrist
Peter Durning, Lived Experience Consultant
Michael Angelini, PharmD Pharmacist

In September 2024, the Food and Drug Administration (FDA) approved the first novel medication for schizophrenia in nearly two decades. With the widespread interest around this new drug, Cobenfy, questions have been raised by providers and patients alike about how the drug works and what it means for the future of psychosis treatment. This panel will bring together experts with backgrounds in research, lived experience, and pharmacy to discuss Cobenfy and its potential impact on psychiatry.

Cobenfy Fact Sheet - Clinicians

Cobenfy Fact Sheet - Patients & Families

(On a Journey toward) Improving Outcomes for Individuals with Psychosis

Dr. Tara Niendam

In this presentation, we will discuss the continuum of psychosis, consider how social and structural factors impact the course of psychosis, and think about how interventions for psychosis (e.g. coordinated specialty care) could address the variety of factors impacting outcomes.

Dr. Tara Niendam (she/her) is a licensed clinical psychologist and a Professor in the UC Davis Department of Psychiatry. Tara Niendam (she/her) identifies as a white, cisgender, heterosexual woman and a consumer of mental health services. She comes to this work from both personal and family experiences. She obtained a B.A. in Psychology from Northwestern University and Ph.D. in Clinical Psychology from the University of California, Los Angeles. As the Executive Director of the UC Davis Early Psychosis Programs (EDAPT and SacEDAPT Clinics), Dr. Niendam supervises clinic and training activities, and coordinates outreach and educational presentations within Sacramento and across California. With funding from the Robert Wood Johnson Foundation, California Mental Health Service Oversight and Accountability Commission, and National Institutes of Mental Health, Dr. Niendam’s research uses mobile health technology to enhance early identification and treatment of youth and young adults with serious mental illness, with a focus on improving clinical and functional outcomes. The EPI-CAL project, led by Dr. Niendam in partnership with UC San Francisco, UC San Diego, University of Calgary, One Mind, and multiple California counties, brings client-level data to the clinician’s fingertips, and enables large scale data-driven approaches to improve outcomes for EP care. She also directs the EPI-CAL Training and Technical Assistance Center, which seeks to bring evidence based early psychosis care to all Californians.

DMH Young Adult Access Centers: Driving Innovation for Young Adult Mental Health Support

Heidi Holland, M.Ed & Ian Sullivan

The focus of the session will be:

• Providing an overview of the Young Adult Access Center model:

• Sharing key data points that show promising outcomes: and

• Hearing  about the experiences of young adults working in and utilizing the services.

Heidi Holland, M.Ed. is the DMH Director of Young Adult Transition Services and was key in the development of Young Adult Peer Mentoring and the Young Adult Access Center models.

Ian Sullivan is a Peer Coordinator at the YouForward Access Center in Everett and has previous experience as a peer at the PEACE early psychosis program. 

One Code to Unite Them All: Billing for Psychosis Care

Monica Luke
2024 Mass-STEP Conference, Day 2

Lived Experience Panel: The Politics of Asking for Support

Mass-STEP Lived Experience Committee
2024 Mass-STEP Conference, Day 2

National Trends in Specialty Care for Early Course Psychosis: Recent Advances & Future Directions

2024 Mass-STEP Conference, Day 2

Integrating Lived Experience to Enhance Clinical Development in the AMP SCZ Program

Carlos Larruari
2024 Mass-STEP Conference, Day 2

Community Spotlight

Understanding and Treating Complex PTSD

Dr. Ryan Madigan, Psy.D

This workshop will orient participants to PTSD and C-PTSD, review key mechanisms of C-PTSD, and discuss strategies and treatment approaches for treating individuals and families with C-PTSD.

Dr. Ryan Madigan founded the Boston Child Study Center (BCSC) in 2013 with the mission to push the mental health field to better understand and treat mental illness by changing antiquated treatment models, unethical reimbursement practices, and social and cultural inequities in the mental health field. Dr. Madigan has taught at the undergraduate, graduate, and post-doctoral levels at Wellesley College, Rutgers University, Boston University, McLean Hospital and Harvard Medical School. As an attending clinician at McLean Hospital, Dr. Madigan co-founded the DBT trauma and exposure program specializing in suicide, non-suicidal self-injury, trauma, personality disorders, and psychosis. His research focuses on the development of a single transdiagnostic intervention for trauma and emotion disorders.

This webinar is co-hosted with the New England Mental Health Technology Transfer Center (MHTTC).

Navigating the Overlap: Psychosis and Bipolar Disorder

Roscoe Brady, MD, PhD
Associate Professor, Harvard Medical School, Vice-Chair of Research, Department of Psychiatry, Beth Israel Deaconess Medical Center

This presentation will explore the role of medications in both treating and preventing mood episodes in bipolar disorder. We'll discuss diagnosis briefly and mainly focus on treating medication resistant mood symptoms in individuals with this diagnosis.

Dr. Brady is an associate professor of psychiatry and vice-chair for research at the Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, Massachusetts. He is well known for his work in improving our understanding of the biological basis and innovative treatments for serious mental illnesses such as bipolar disorder and schizophrenia. 

This webinar is co-hosted with the New England Mental Health Technology Transfer Center (MHTTC).